2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.08D.03 Efficacy of Neoadjuvant Immunochemotherapy in the Treatment of Stage III Non-Small-Cell Lung Cancer with Cancer-driven Gene Mutations

EP.08D.03 Efficacy of Neoadjuvant Immunochemotherapy in the Treatment of Stage III Non-Small-Cell Lung Cancer with Cancer-driven Gene Mutations

Back to course

Pdf Summary

This study assessed the efficacy and safety of neoadjuvant immunochemotherapy in stage III non-small cell lung cancer (NSCLC) patients with cancer-driven gene mutations. The retrospective analysis involved 34 patients with stage III NSCLC, who were categorized into those with cancer-driven gene mutations (mutation group, n=22) and those without (wild type [WT] group, n=12). The primary endpoint was pathological response, while secondary endpoints included objective response rate (ORR), disease-free survival (DFS), overall survival (OS), and adverse events (AEs).<br /><br />The results showed that the major pathological response (MPR) was 75.0% in the WT group and 47.0% in the mutation group. However, this difference was not statistically significant (P=0.234). The pathological complete response (pCR) rates were 37.5% and 23.5%, respectively (P=0.640). The partial response (PR) rate was 58.3% in the WT group and 68.2% in the mutation group, with no significant difference (P=0.566). <br /><br />DFS and OS did not statistically differ between the groups, with the 1-year DFS rates at 87.5% for the WT group and 82.4% for the mutation group, while the 1-year OS rates were 100.0% and 94.1%, respectively. The incidence of adverse events was generally low and comparable between groups, with no grade 3 or 4 events observed. Grade 1 and 2 AEs occurred in 72.7% of the mutation group and 91.7% of the WT group (P=0.05).<br /><br />In conclusion, neoadjuvant immunochemotherapy was feasible and safe, showing considerable therapeutic effects for stage III NSCLC patients, regardless of the presence of cancer-driven gene mutations. Further research is warranted to solidify these findings and improve treatment strategies.

Asset Subtitle

Jiacong Liu

Meta Tag

Speaker Jiacong Liu

Topic Local-Regional Non-small Cell Lung Cancer

Keywords

neoadjuvant immunochemotherapy

stage III NSCLC

cancer-driven gene mutations

pathological response

objective response rate

disease-free survival

overall survival

adverse events

retrospective analysis

therapeutic effects